Theorem Clinical Research

R&D Trends

NIH programs to focus on emerging areas of science

Wednesday, July 30, 2014 12:40 PM

Scientific areas ripe for targeted investments in technology development and research to improve health are the focus of new programs of the NIH’s Common Fund. The programs include work to facilitate the study of how sugar modifications affect proteins, to understand the arrangement of DNA within cells in four dimensions and to enable the development of new therapies that allow control of organ function through manipulation of nerves.

More... »


Report: Increasing potential for in vitro diagnostics in drug development process

Wednesday, July 30, 2014 12:39 PM

Bionest Partners, a life science industry strategic consulting firm, has found an increased potential for in vitro diagnostics in the drug development process.

More... »


Cloud Pharmaceuticals receives $150,000 phase I grant from NSF SBIR

Wednesday, July 30, 2014 12:37 PM

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has been awarded a phase I grant from the National Science Foundation Small Business Innovation Research (NSF SBIR) program. The grant is valued at $150,000.

More... »

Report: Generics increase to more than 75% of all 2013 prescriptions in England, Wales

Monday, July 28, 2014 03:04 PM

Usage of generic medicines in England and Wales increased to more than three-quarters of all NHS prescriptions in 2013, according to the latest figures supplied by the Health and Social Care Information Center (HSCIC).

More... »

NIAID awards SRI International $49M to study new therapies for HIV and AIDS

Monday, July 28, 2014 03:02 PM

SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing sexual transmission of HIV.

More... »

RB to invest $170M to build U.K. R&D center

Monday, July 28, 2014 02:59 PM

RB, a global consumer health and hygiene company formerly called Reckitt Benckiser, will invest $170 millionin its consumer health R&D operations with the creation of a state-of-the-art Center of Scientific Excellence to be based in the U.K.

More... »

Xention awarded $2.4M from Technology Strategy Board for atrial fibrillation medicines

Monday, July 28, 2014 02:56 PM

Xention, a Cambridge-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, was awarded $2.4 million from the Technology Strategy Board, a U.K. innovation agency, to progress its novel IKAChchannel blockers through preclinical development.

More... »

Shire, ArmaGen ink agreement

Monday, July 28, 2014 02:55 PM

Shire, a global specialty biopharmaceutical company, and ArmaGen, a U.S. privately held biotechnology company, have announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

More... »

Bristol-Myers Squibb, Ono Pharmaceutical collaborate in Japan, South Korea, Taiwan

Monday, July 28, 2014 02:54 PM

Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

More... »

Qiagen, AstraZeneca collaborate for lung cancer patients

Monday, July 28, 2014 02:53 PM

Qiagen, a Netherlands-based holding company, has announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AZ's targeted therapy for non-small cell lung cancer (NSCLC).

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs